BIOFARM S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.752 RON | -1.57% |
|
-0.53% | -8.74% |
| May. 14 | Biofarm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Feb. 28 | Biofarm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 277M 60.56M | Sales 2023 | 280M 61.29M | Capitalization | 812M 178M |
|---|---|---|---|---|---|
| Net income 2022 | 70M 15.31M | Net income 2023 | 77M 16.84M | EV / Sales 2022 | 1.89 x |
| Net cash position 2022 | 82.71M 18.09M | Net cash position 2023 | 112M 24.42M | EV / Sales 2023 | 2.5 x |
| P/E ratio 2022 |
9.31
x | P/E ratio 2023 |
11.6
x | Employees | 399 |
| Yield 2022 |
4.87% | Yield 2023 |
3.76% | Free-Float | 11.67% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.57% | ||
| 1 week | -0.53% | ||
| Current month | -1.83% | ||
| 1 month | -7.84% | ||
| 3 months | -10.69% | ||
| 6 months | -7.84% | ||
| Current year | -8.74% |
1 week
0.75
0.78
1 month
0.720.82
Current year
0.720.91
1 year
0.610.91
3 years
0.530.91
5 years
0.310.91
10 years
0.210.91
| Managers | Title | Age | Since |
|---|---|---|---|
Catalin Vicol
CEO | Chief Executive Officer | 49 | 18-11-14 |
Mihai Zoescu
DFI | Director of Finance/CFO | 44 | 21-01-17 |
Lucian Bogaciu
ADM | Chief Administrative Officer | 50 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Catalin Vicol
CEO | Chief Executive Officer | 49 | 18-11-14 |
| Director/Board Member | 44 | 15-12-09 | |
| Director/Board Member | 49 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-04 | 0.752 | -1.57% | 63,556 |
| 24-06-03 | 0.764 | -0.26% | 62,818 |
| 24-05-31 | 0.766 | 0.00% | 23,168 |
| 24-05-30 | 0.766 | -0.52% | 14,180 |
| 24-05-29 | 0.77 | +1.85% | 67,215 |
End-of-day quote Bucharest S.E., June 03, 2024
More quotes
Biofarm SA is a Romania-based company engaged in the pharmaceutical sector. The Company focuses on the production and marketing of pharmaceutical preparations. The Company is active in the manufacture and wholesale of over the counter drugs, prescription medications and dietary supplements. The Companyâs product portfolio includes pharmaceutical preparations for digestive system, musculoskeletal system, immune stimulation, respiratory system, cold and flu symptoms and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants and cosmetics, among others. Additionally, the Company offers services, such as consultancy on Romanian pharmaceutical market, manufacturing of non-sterile products, the investment in research, promotion and packaging. The main shareholder of the Company is Societatea de Investitii Financiare Muntenia SA.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -8.74% | 162M | |
| +18.07% | 41.07B | |
| +24.16% | 22.65B | |
| +20.46% | 14.14B | |
| +53.83% | 12.09B | |
| -0.05% | 6.79B | |
| -10.97% | 6.91B | |
| -8.87% | 5.73B | |
| +15.28% | 5.59B | |
| +4.00% | 4.82B |
- Stock Market
- Equities
- BIO Stock
